64 related articles for article (PubMed ID: 22068464)
1. Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study.
Shimabukuro T; Sakano S; Matsuda K; Kamiryo Y; Yamamoto N; Kaneda Y; Nasu T; Baba Y; Suga A; Yamamoto M; Aoki A; Takai K; Yoshihiro S; Konishi M; Imoto K; Matsuyama H
Int J Clin Oncol; 2013 Feb; 18(1):62-7. PubMed ID: 22068464
[TBL] [Abstract][Full Text] [Related]
2. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.
Harshman LC; Chen YH; Liu G; Carducci MA; Jarrard D; Dreicer R; Hahn N; Garcia JA; Hussain M; Shevrin D; Eisenberger M; Kohli M; Plimack ER; Cooney M; Vogelzang NJ; Picus J; Dipaola R; Sweeney CJ;
J Clin Oncol; 2018 Feb; 36(4):376-382. PubMed ID: 29261442
[TBL] [Abstract][Full Text] [Related]
3. Clinical Outcomes of Patients with High-risk Metastatic Hormone-naïve Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study.
Miyake H; Matsumoto R; Fujimoto K; Mizokami A; Uemura H; Kamoto T; Kawakami S; Nakamura K; Maekawa S; Shibayama K; Watanabe A; Ito M; Tajima Y; Matsuyama H; Uemura H
Eur Urol Oncol; 2024 Jun; 7(3):625-632. PubMed ID: 38296736
[TBL] [Abstract][Full Text] [Related]
4. A territory-wide real-world efficacy and toxicity analysis of abiraterone acetate versus docetaxel in 574 Asian patients with metastatic hormone-sensitive prostate cancer.
Lam BHW; Tsang VHM; Lee MP; Chan K; Liu TC; Ng BYH; Wo BBW; Leung KC; Mui WH; Chan TW; Lam MHC; Siu SWK; Poon DMC
Clin Genitourin Cancer; 2024 Feb; 22(1):e75-e85.e1. PubMed ID: 37604745
[TBL] [Abstract][Full Text] [Related]
5. Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors.
Gebrael G; Sayegh N; Thomas VM; Chigarira B; Tripathi N; Jo YJ; Li H; Sahu KK; Srivastava A; McFarland T; Maughan BL; Swami U; Agarwal N
Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):279-282. PubMed ID: 37460732
[TBL] [Abstract][Full Text] [Related]
6. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
Sweeney CJ; Chen YH; Carducci M; Liu G; Jarrard DF; Eisenberger M; Wong YN; Hahn N; Kohli M; Cooney MM; Dreicer R; Vogelzang NJ; Picus J; Shevrin D; Hussain M; Garcia JA; DiPaola RS
N Engl J Med; 2015 Aug; 373(8):737-46. PubMed ID: 26244877
[TBL] [Abstract][Full Text] [Related]
7. Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
Rajan P; Frew JA; Wilson JM; Azzabi AS; McMenemin RM; Stockley J; Soomro NA; Durkan G; Pedley ID; Leung HY
Urol Oncol; 2015 Aug; 33(8):337.e1-6. PubMed ID: 26092557
[TBL] [Abstract][Full Text] [Related]
8. Effect of Upfront Docetaxel in De Novo Metastatic Castration-Sensitive Prostate Cancer Patients with Gleason Grade Group 5.
Yildirim S; Yilmaz C
J Coll Physicians Surg Pak; 2023 Nov; 33(11):1310-1314. PubMed ID: 37926887
[TBL] [Abstract][Full Text] [Related]
9. Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate Cancer.
Briones J; Khan M; Sidhu AK; Zhang L; Smoragiewicz M; Emmenegger U
Front Oncol; 2021; 11():658331. PubMed ID: 34026638
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of classical secondary hormonal therapies prior to docetaxel therapy in Japanese patients with castration-resistant prostate cancer: Multicenter retrospective study.
Kandori S; Yoshino T; Tsutsumi M; Yamauchi A; Ohtani M; Fukuhara Y; Miyanaga N; Miyazaki J; Nishiyama H; Shimazui T
Prostate Int; 2016 Dec; 4(4):140-144. PubMed ID: 27995113
[TBL] [Abstract][Full Text] [Related]
11. Improvement of a predictive model of castration-resistant prostate cancer: functional genetic variants in TGFβ1 signaling pathway modulation.
Teixeira AL; Gomes M; Nogueira A; Azevedo AS; Assis J; Dias F; Santos JI; Lobo F; Morais A; Maurício J; Medeiros R
PLoS One; 2013; 8(8):e72419. PubMed ID: 23951322
[TBL] [Abstract][Full Text] [Related]
12. Whole blood stem cell reinfusion and escalated dose melphalan in castration-resistant prostate cancer: a phase 1 study.
Shamash J; Jacob J; Agrawal S; Powles T; Mutsvangwa K; Wilson P; Stebbing J
Clin Cancer Res; 2012 Apr; 18(8):2352-9. PubMed ID: 22392912
[TBL] [Abstract][Full Text] [Related]
13. A comparison of androgen deprivation therapy versus surgical castration for patients with advanced prostatic carcinoma.
Lin YH; Chen CL; Hou CP; Chang PL; Tsui KH
Acta Pharmacol Sin; 2011 Apr; 32(4):537-42. PubMed ID: 21399652
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment Lymphocyte to C-Reactive Protein Ratio: An Independent Predictor of Overall Survival in Metastatic Hormone-Naïve Prostate Cancer Patients.
Sasaki T; Takahashi T; Sekito S; Kanda H; Higashi S; Masui S; Kojima T; Matsuura H; Nishikawa K; Akamatsu S; Okugawa Y; Kobayashi T; Inoue T
Clin Genitourin Cancer; 2023 Dec; 21(6):e474-e484. PubMed ID: 37301664
[TBL] [Abstract][Full Text] [Related]
15. Manganese as a Possible Anticancer Enhancer in Docetaxel Treatment of Prostate Cancer Cells.
Holm I; Hernroth B; Rosander A; Tassidis H
Anticancer Res; 2024 Mar; 44(3):953-962. PubMed ID: 38423638
[TBL] [Abstract][Full Text] [Related]
16. Prediction of treatment efficacy for prostate cancer using a mathematical model.
Peng H; Zhao W; Tan H; Ji Z; Li J; Li K; Zhou X
Sci Rep; 2016 Feb; 6():21599. PubMed ID: 26868634
[TBL] [Abstract][Full Text] [Related]
17. The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer.
Oka T; Hatano K; Okuda Y; Yamamoto A; Uemura T; Yamamichi G; Tomiyama E; Ishizuya Y; Yamamoto Y; Kato T; Kawashima A; Fujita K; Nonomura N
Int J Clin Oncol; 2023 Mar; 28(3):427-435. PubMed ID: 36580184
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients - A propensity scoring approach.
Nagao K; Matsuyama H; Nozawa M; Hara I; Nishioka T; Komura T; Esa A; Uejima S; Imanishi M; Uekado Y; Ogawa T; Kajikawa H; Uemura H
Asian J Urol; 2016 Jan; 3(1):33-38. PubMed ID: 29264160
[TBL] [Abstract][Full Text] [Related]
19. Impact of local treatment on overall survival of patients with metastatic prostate cancer: systematic review and meta-analysis.
Carneiro A; Baccaglini W; Glina FPA; Kayano PP; Nunes VM; Smaletz O; Bernardo WM; Carvalho IT; Lemos GC
Int Braz J Urol; 2017; 43(4):588-599. PubMed ID: 27802009
[TBL] [Abstract][Full Text] [Related]
20. Low-dose docetaxel, estramustine and prednisolone combination chemotherapy for castration-resistant prostate cancer.
Nakano M; Shoji S; Higure T; Kawakami M; Tomonaga T; Terachi T; Uchida T
Mol Clin Oncol; 2016 Jun; 4(6):942-946. PubMed ID: 27284427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
